Inspired by personal experiences, Intellia in biotech seeks to address genetic, oncological, and immunological diseases. Their CRISPR-based genome editing technologies, including those pioneered by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier, aim for groundbreaking medical advancements. With a modular genome editing platform, they create in vivo and ex vivo therapies for diverse indications. Intellia’s commitment lies in making CRISPR-based treatments a reality for genetic disorders and crafting innovative cell therapies for cancers and autoimmune conditions.
